FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/17/2024
Back to search
Official data from USPTO
CENYX BIOTECH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CENYX BIOTECH
ST13
US500000079343374Class
5, 42
Filing
79343374
Registration
7333739
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
11/17/2024
Trademark type
Word
Nice classes
5, 42
Filing date
04/29/2022
Registration date
03/26/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/26/2024
Last transaction
03/26/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
SIMCOX,KYLE DUNCAN
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Cenyx Biotech Inc.
Representatives
Leigh Ann Lindquist SUGHRUE MION, PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Diagnostic reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; veterinary preparations for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes for animal and poultry; radio-isotope markers for therapeutic or diagnostic use; in vitro diagnostic preparations for medical purposes; vaccines; contrast media for use in medical imaging equipment; contrast media for in vivo imaging; drug delivery agents in the form of compoundswrapping wafersedible wafers that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the prevention of inflammatory disorders; non-prescription medicinesmedicinal preparations in the nature of pillstabletscapsulescapletsliquid dropssachetsoral liquidssuspensionsliquidssemi-solidscreamssyrupsointmentslotionsgelsspraysemulationsoilspessariessuppositoriesgranules and films for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes; radioactive pharmaceutical preparations for use in vivo diagnostics or therapeutic use; diagnostic agents for medical purposes; biological preparations for medical purposesbiological preparations for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes for medical or veterinary purposes; pharmaceuticals for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the treatment of cardiovascular disease; drug delivery agents in the form of tablets or capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of inflammatory diseases; antibodies for medical purposes
Class 42
Scientific research in the nature of conducting clinical trials for others in the field of cardiovascular disease; scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research and development; Scientific research in the nature of conducting clinical trials for others in the field of medicine; analysisevaluation of medical product development services of others to assure compliance with industry standards; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy
Publications
History of USPTO decisions and trademark events.
34 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/06/2024
FIMP
FINAL DISPOSITION PROCESSED
10/06/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/27/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/26/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/26/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/09/2024
PUBO
PUBLISHED FOR OPPOSITION
01/09/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/08/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/20/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/20/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/20/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/18/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/29/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/29/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
11/29/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/29/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
11/29/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/29/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/29/2023
DOCK
ASSIGNED TO EXAMINER
11/07/2023
DOCK
ASSIGNED TO EXAMINER
11/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/24/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/24/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/24/2023
RFNT
REFUSAL PROCESSED BY IB
05/24/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/30/2023
RFRR
REFUSAL PROCESSED BY MPU
04/30/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/11/2023
CNRT
NON-FINAL ACTION WRITTEN
03/10/2023
DOCK
ASSIGNED TO EXAMINER
02/17/2023
MAFR
APPLICATION FILING RECEIPT MAILED
06/28/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/24/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/23/2022
Continuous trademark protection
Get notified about every new filing that threatens CENYX BIOTECH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.